1 Min Read
June 26 (Reuters) - Atossa Genetics Inc
* Atossa genetics says received positive interim safety assessment of first cohort receiving proprietary oral endoxifen in phase 1 dose escalation study Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.